Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3579 ↗At a glance
Übersichtsarbeit in Clinical Pharmacology & Therapeutics, 2025. Written by Sarah K Emond and 2 co-authors. Institution: Institute for Clinical and Economic Review, Boston, Massachusetts, USA. Major MEDLINE topics: Technology Assessment, Biomedical, Health Services Accessibility, Evidence-Based Medicine. Cited 4 times so far (Crossref); 60 references.
Abstract (original language)
Conducting high‐quality health technology assessments requires high‐quality evidence. With evolving regulatory standards for faster approval of new pharmaceutical products, health technology practitioners often find that the evidence base available to inform their work is lacking. This review article provides case examples of how health technology assessors have grappled with this tension, from the United States and European perspective, including experiences with new therapies for large populations, such as Alzheimer's disease, and gene therapies for ultra‐rare conditions. The article concludes by offering some potential policy solutions that can meet the goals of robust evidence generation, patient access, and system affordability, including reimbursement with evidence development, outcomes‐based contracts, and other types of managed entry agreements.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Institute for Clinical and Economic Review, Boston, Massachusetts, USA.
- Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Utrecht, The Netherlands.
- National Health Care Institute, Diemen, The Netherlands.
- Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts, USA.
ORCID profiles: Daniel A Ollendorf
Cite
APA
Emond, S. K., Goettsch, W. G., & Ollendorf, D. A. (2025). Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3579
Vancouver
Emond SK, Goettsch WG, Ollendorf DA. Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3579
BibTeX
@article{Emond2025,
author = {Emond, Sarah K and Goettsch, Wim G and Ollendorf, Daniel A},
title = {Harmonizing HTA Evidence Needs and Expectations: Challenges and Opportunities to Improve Evidence Generation, Ensure Access and Affordability},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3579}
}
EUVIMED